Anifrolumab (Saphnelo) Gets Green Light for Approval in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for anifrolumab (Saphnelo) as an add-on treatment for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy, according to an announcement on Dec. 16.

Anifrolumab, a monoclonal antibody that binds to subunit 1 of the type I interferon receptor and thereby blocks the biologic activity of type I interferons, was approved by the US Food and Drug Administration in July 2021.

The recommendation for anifrolumab is based on its ability to elicit a clinical response on the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at week 52, which is defined as improvement in all organ domains with moderate or severe SLE activity at baseline.

The manufacturer AstraZeneca said the biologic drug will be available as a 300 mg concentrate for solution for infusion.

The most common adverse reactions are upper respiratory tract infection, bronchitis, infusion-related reaction, and herpes zoster. The most common serious adverse reaction was herpes zoster.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Statement from Agriculture Secretary Tom Vilsack on the Confirmation of Xochitl Torres Small as Deputy Secretary of the U.S. Department of Agriculture thumbnail

Statement from Agriculture Secretary Tom Vilsack on the Confirmation of Xochitl Torres Small as Deputy Secretary of the U.S. Department of Agriculture

Washington, July 11, 2023 – Today, Agriculture Secretary Tom Vilsack made the following statement on the confirmation of Xochitl Torres Small as Deputy Secretary of the U.S. Department of Agriculture (USDA). "Xochitl Torres Small has dedicated her career to serving the agriculture industry and the American people, and I have witnessed her lead with energy
Read More
Study: Metformin's impact on aging and longevity through DNA methylation thumbnail

Study: Metformin’s impact on aging and longevity through DNA methylation

Age acceleration between metformin users and nonusers among the diabetes group. Credit: Aging (2023). DOI: 10.18632/aging.204498 A new research paper was published in Aging, titled "Metformin use history and genome-wide DNA methylation profile: potential molecular mechanism for aging and longevity." Metformin, a commonly prescribed anti-diabetic medication, has repeatedly been shown to hinder aging in pre-clinical
Read More
Index Of News
Total
0
Share